GeneDx Holdings Corp., a genomics-related diagnostic and information services company, has received a consensus recommendation of “Moderate Buy” from six ratings firms currently covering the stock, according to MarketBeat Ratings. Among the analysts, three have rated the stock as a hold, while three have given it a buy recommendation. The average 12-month price target among these analysts is $38.00.
Several equities research analysts have shared their opinions on GeneDx. Wells Fargo & Company initiated coverage on the company, assigning it an “equal weight” rating and a $34.00 price target. The Goldman Sachs Group increased their price objective from $28.00 to $32.00 and gave the stock a “neutral” rating. TD Cowen raised their price target to $50.00 and rated the stock as a “buy.” Jefferies Financial Group started coverage with a “hold” rating and a $21.00 target price. Craig Hallum also raised their target price to $46.00 and gave the stock a “buy” rating.
In the latest quarterly earnings report released on July 30th, GeneDx reported earnings per share of ($0.11), surpassing analysts’ consensus estimates of ($0.26) by $0.15. The company had a negative net margin of 48.21% and a negative return on equity of 22.71%. Its revenue for the quarter was $70.51 million, exceeding analysts’ expectations of $58.90 million. Analysts predict that GeneDx will post an EPS of -0.75 for the current fiscal year.
In terms of insider activity, CEO Katherine Stueland sold 3,639 shares of GeneDx stock at an average price of $33.33, totaling $121,287.87. Following this transaction, Stueland now holds 95,457 shares valued at approximately $3,181,581.81. CFO Kevin Feeley also sold 895 shares at an average price of $33.33, amounting to $29,830.35. Feeley now owns 39,910 shares valued at around $1,330,200.30. Insiders have collectively sold 743,868 shares worth $24,114,996 in the last ninety days, with company insiders owning 28.10% of the stock.
Several institutional investors have recently adjusted their positions in GeneDx. Acadian Asset Management LLC acquired a new stake in the company during the second quarter, valued at approximately $34,000. nVerses Capital LLC also purchased a new position in the second quarter, worth about $50,000. Thompson Davis & CO. Inc. increased its holdings by 20.8% in the first quarter, now owning 24,094 shares valued at $220,000. American Century Companies Inc. raised its position by 36.1% in the second quarter, holding 17,258 shares valued at $451,000. Additionally, The Manufacturers Life Insurance Company acquired a new position in the second quarter, worth approximately $290,000. Hedge funds and other institutional investors now own 61.72% of the company’s stock.
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company’s AI-driven health intelligence platform, Centrellis, integrates digital tools and artificial intelligence to deliver comprehensive health insights by synthesizing clinical and genomic data.